22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          High mobility group box 1 (HMGB1) is an abundant and ubiquitous nuclear DNA-binding protein that has multiple functions dependent on its cellular location. HMGB1 binds to DNA, facilitating numerous nuclear functions including maintenance of genome stability, transcription, and repair. However, little is known about the effects of nuclear HMGB1 on cardiac hypertrophy and heart failure. The aim of this study was to examine whether nuclear HMGB1 plays a role in the development of cardiac hypertrophy induced by pressure overload.

          Methods and results

          Analysis of human biopsy samples by immunohistochemistry showed decreased nuclear HMGB1 expression in failing hearts compared with normal hearts. Nuclear HMGB1 decreased in response to both endothelin-1 (ET-1) and angiotensin II (Ang II) stimulation in neonatal rat cardiomyocytes, where nuclear HMGB1 was acetylated and translocated to the cytoplasm. Overexpression of nuclear HMGB1 attenuated ET-1 induced cardiomyocyte hypertrophy. Thoracic transverse aortic constriction (TAC) was performed in transgenic mice with cardiac-specific overexpression of HMGB1 (HMGB1-Tg) and wild-type (WT) mice. Cardiac hypertrophy after TAC was attenuated in HMGB1-Tg mice and the survival rate after TAC was higher in HMGB1-Tg mice than in WT mice. Induction of foetal cardiac genes was decreased in HMGB1-Tg mice compared with WT mice. Nuclear HMGB1 expression was preserved in HMGB1-Tg mice compared with WT mice and significantly attenuated DNA damage after TAC was attenuated in HMGB1-TG mice.

          Conclusion

          These results suggest that the maintenance of stable nuclear HMGB1 levels prevents hypertrophy and heart failure by inhibiting DNA damage.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

          High Mobility Group 1 protein (HMGB1) is a chromatin component that, when leaked out by necrotic cells, triggers inflammation. HMGB1 can also be secreted by activated monocytes and macrophages, and functions as a late mediator of inflammation. Secretion of a nuclear protein requires a tightly controlled relocation program. We show here that in all cells HMGB1 shuttles actively between the nucleus and cytoplasm. Monocytes and macrophages acetylate HMGB1 extensively upon activation with lipopolysaccharide; moreover, forced hyperacetylation of HMGB1 in resting macrophages causes its relocalization to the cytosol. Cytosolic HMGB1 is then concentrated by default into secretory lysosomes, and secreted when monocytic cells receive an appropriate second signal.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Trends in heart failure incidence and survival in a community-based population.

            The epidemic of heart failure has yet to be fully investigated, and data on incidence, survival, and sex-specific temporal trends in community-based populations are limited. To test the hypothesis that the incidence of heart failure has declined and survival after heart failure diagnosis has improved over time but that secular trends have diverged by sex. Population-based cohort study using the resources of the Rochester Epidemiology Project conducted in Olmsted County, Minnesota. Patients were 4537 Olmsted County residents (57% women; mean [SD] age, 74 [14] years) with a diagnosis of heart failure between 1979 and 2000. Framingham criteria and clinical criteria were used to validate the diagnosis Incidence of heart failure and survival after heart failure diagnosis. The incidence of heart failure was higher among men (378/100 000 persons; 95% confidence interval [CI], 361-395 for men; 289/100 000 persons; 95% CI, 277-300 for women) and did not change over time among men or women. After a mean follow-up of 4.2 years (range, 0-23.8 years), 3347 deaths occurred, including 1930 among women and 1417 among men. Survival after heart failure diagnosis was worse among men than women (relative risk, 1.33; 95% CI, 1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43% in 1979-1984 vs 52% in 1996-2000, P<.001). However, men and younger persons experienced larger survival gains, contrasting with less or no improvement for women and elderly persons. In this community-based cohort, the incidence of heart failure has not declined during 2 decades, but survival after onset of heart failure has increased overall, with less improvement among women and elderly persons.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Heart failure.

                Bookmark

                Author and article information

                Journal
                Cardiovasc Res
                Cardiovasc. Res
                cardiovascres
                cardiovascres
                Cardiovascular Research
                Oxford University Press
                0008-6363
                1755-3245
                1 September 2013
                25 May 2013
                25 May 2013
                : 99
                : 4
                : 657-664
                Affiliations
                [1 ]Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine , 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
                [2 ]Department of Pharmacology, College of Medicine , Yeungnam University , Daegu, Korea
                [3 ]Aab Cardiovascular Research Institute, University of Rochester , Rochester, NY, USA
                [4 ]Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan
                [5 ]Department of Cardiology and Hematology, Fukushima Medical University , Fukushima, Japan
                Author notes
                [* ]Corresponding author. Tel: +81 23 628 5302; Fax: +81 23 628 5305, Email: tshishid@ 123456med.id.yamagata-u.ac.jp
                Article
                cvt128
                10.1093/cvr/cvt128
                3746952
                23708738
                4ff5417a-2c44-4588-863a-244380ff151e
                © The Author 2013. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 5 September 2012
                : 25 March 2013
                : 18 May 2013
                Categories
                Original Articles
                Cardiac Biology and Remodelling
                Custom metadata
                Time for primary review: 32 days

                Cardiovascular Medicine
                hmgb1,heart failure,acetylation,translocation,pressure overload
                Cardiovascular Medicine
                hmgb1, heart failure, acetylation, translocation, pressure overload

                Comments

                Comment on this article